Overview
RightEye develops eye-tracking health technology with an FDA-cleared system that records, views, and analyzes eye movements to assess visual and brain health. It runs five-minute, game-like tests, records eye movements, and produces a report that compares results to a normative database to provide objective diagnostic data. The platform combines hardware and software used by optometrists, hospitals, and sports teams for concussion screening, functional vision assessment, and early Parkinson’s detection. Its goal is to shift visual and neurological health from subjective observation to quantitative, trackable data to improve diagnosis, monitoring, and patient outcomes.
Work here?Claim your company
Simplify's take
What believers are saying
- RightEye’s November 3, 2025 Sensorimotor launch directly targets reimbursable optometry workflow adoption.
- Tobii’s February 27, 2026 customer story reinforces an active partner relationship around Parkinson’s detection.
- Insurance reimbursement under CPT 92060 lowers purchase friction for practices facing capital constraints.
What critics are saying
- FDA’s December 20, 2022 warning letter attacked Parkinson’s, concussion, and ADHD marketing claims.
- HarmonEyes acquired iFocus Health on December 11, 2025, intensifying eye-tracking competition in clinics.
- If FDA narrows claims again, RightEye’s Parkinson’s narrative and reimbursement-led sales collapse quickly.
What makes RightEye unique
- RightEye’s Sensorimotor System launched November 3, 2025 with CPT 92060 reimbursement.
- The FDA-cleared Vision System records, views, and analyzes eye movements for visual tracking impairment.
- RightEye still owns rare FDA Breakthrough Device status for its Parkinson’s assessment, granted December 3, 2019.
Help us improve and share your feedback! Did you find this helpful?